Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.41 |
| ▸ | BRAF | P15056 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13587537 | 0.88 | P2RX7 (0.47) | P2RX7TRPV1BRAFMAPK1 | |
| SCHEMBL13587822 | 0.87 | P2RX7 (0.36) | P2RX7TRPV1 | |
| SCHEMBL1590853 | 0.78 | P2RX7 (0.56) | P2RX7TRPV1 | |
| SCHEMBL1590798 | 0.78 | P2RX7 (0.68) | P2RX7TRPV1 | |
| SCHEMBL1590681 | 0.78 | P2RX7 (0.56) | P2RX7TRPV1 | |
| SCHEMBL1590683 | 0.78 | P2RX7 (0.56) | P2RX7TRPV1 | |
| SCHEMBL12725009 | 0.71 | P2RX7 (0.45) | P2RX7TRPV1 | |
| SCHEMBL13587538 | 0.70 | P2RX7 (0.65) | P2RX7TRPV1 | |
| SCHEMBL13587826 | 0.69 | P2RX7 (0.34) | P2RX7TRPV1 | |
| SCHEMBL13587554 | 0.68 | FFAR2 (0.41) | P2RX7MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | RENOVIS, INC. | 2009-12-03 | — | — | US | disclosed |
| EP-1996585-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | Renovis, Inc. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109154-A2 | BICYCLOHETEROARYL COMPOUNDS AS P2X7 MODULATORS AND USES THEREOF | RENOVIS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298825-A1 | Bicycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX1 | P2RX7 1/4885TRPV1 19/4885BRAF 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.